PowerPoint Presentation
Quininibs: More Vision, Less Needle.
Life Sciences, Med Tec and Digital HealthFutureHealth
SummitDublin May 2016
Breandn N. Kennedy Ph.D. Co-founder Phision TherapeuticsSenior
Lecturer (Pharmacology)UCD School of Biomolecular & Biomedical
ScienceUCD Conway InstituteDUBLIN, IRELAND.
[email protected]
1
THE PROBLEM
BlindnessIneffective & Inefficient Treatments
US Retinal Therapeutics Market : $3.5 billion Develop More
Effective Drugs and Improved Drug Delivery Systems for Treatment of
Blindness Linked to Diabetes or Ageing. Opportunity.
Imagine going blind. Consider the impact of no longer being able
to read, drive or recognize the faces of loved ones. This is the
situation facing the 6 million people in Europe losing vision due
to ageing or diabetes. Current Txs are undesired by end users due
to the frequency of injections (6-12) and the non-responder rates
(20-30%). The ocular therapeutics market is a relatively new and
growing market with US sales of ~4 billion.This market is open to
disruption as evidenced by Eylea capturing ~50% of marker share in
4 years.
2
THE END USERSX
PATIENTCLINICIAN USERPain 1: Clinical Tsunami of Eye
Injections.Pain 2: 30% Non-Responder Patients.Pain 3: Risk of Eye
Infection or Retinal Detachment.
Pain 1: Loss of Vision & Loss of Independence.Pain 2: 6-12x
Eye Injections Per Year.Pain 3: No Alternative if Non-Responder or
Refractory
3
FOUNDERS -Breandn Kennedy, Ph.D.-Senior Lecturer UCD -Vision
Research (USA & Ireland) > 20 yrs
-Jacintha OSullivan, Ph.D.-Associate Professor, TCD-Cancer
research (USA & Ireland) > 20 yrs
RESEARCH LEADERS-Alison Reynolds PhD-Ocular Drug Discovery.
-Orla Galvin Ph.D.-Ocular Drug Delivery.
-Clare Butler-Cancer Models.
COLLABORATORS-Prof. A. Pandit. -Prof. A. Sjolander.-Prof. A.
Stitt.-Prof. F. OBrien
FUNDERS
ADVISORS
-Consultant Ophthalmologists
TEAM
THE TEAM
4-My co-founder and I have significant international research
experience.-We have established a mature network of expert
researchers and advisors from industry and academia. -We have a
track-record of national and international research grant
investment in this project, particularly from an EI CF. 4
THE TECHNOLOGY DIFFERENTIATIONUnbiased Drug Discovery In
Vivo.Novel Small Molecule Drugs.Novel Mechanism of Action
(non-VEGF).
Composition of Matter Patents.
Biodegradable Microcapsule Formulations Sustained Release for
4-6 mo.
Phenotype-based Drug Discovery
ReductionistSystemic10 micron drug-loaded microneedles
-We take a different approach to drug discovery. -Pharma
typically identifies a small number of proteins/genes that are
altered in disease and develop many drugs to these targets.
Frequently, these drugs have no have on the disease. -In contrast,
we adopt a system-wide approach (less efficient, more effective) to
discover drugs that do directly change the disease phenotype.
-As a result..5
VEGFR*
VEGF
Decreased Leaky Blood VesselsX
Anti-VEGF biologics
QUININIB
CYSLTR1*
cysLT
Decreased Leaky Blood VesselsX
Y
NOVELTY & PROOF OF PRINCIPLE
-Not surprisingly, The Minimalist approach has resulted in all 3
currently approved drugs working by the same signalling mechanism.
-Our unbiased approach, discovered a new drug with a novel MoA.
-Alone or in combination this drug has potential to reduce
injection frequency or treat non-responder patients.
-Key Proof of principle demonstrating that quininib is effective
include i) reduced number or human tubules in a dish, reduced
development of green blood vessels in the eye and iii) an increases
area of eye without new blood vessels (area inside dashed lines).
6
SUSTAINED OCULAR DELIVERY
Mechanism of Action
Manufac. & Formulation
INVESTMENT & RETURNSeed Funds 400KSeries A 1000KSeries B
4000KPre-clinical StudiesPhase I-II Studies***
**~100 Million (upfront)~700 Million (milestone)30%
royalties
*~10 Million (upfront)~155 Million (milestone)12.5%
royalties
TraconSanten licensed anti-endoglin antibodies for wet-AMD;
stage PC (preclinical); upfront fee $10 M, $155 milestone payments;
royalties 7-13%FovistaOphthotech licensed Fovista to Novartis ex-US
(terrorities outside US); Stage entering PIII; $200 m upfront,
milestones $700 million +; royalties 34-36%
9
Q-DrUGS.A Novel Drug series for BLINDNESS Of AGING &
DIABETES.
Dr. Breandn Kennedy B.Sc. Pharmacology, Ph.D. PharmacologyUCD
Senior Lecturer in PharmacologyLead Co-ordinator FP7 IAPP
3D-NETDirector UCD Ocular Pharmacology GroupDirector UCD Zebrafish
FacilityUCD Conway FellowTel: +353
[email protected]
Investment Capital Domain Expertise Business Networks
Track-Record Synergy
-We are seeking financial capital to progress development of our
technology in a spin-out company. -We are seeking human capital to
enhance the business acumen of our team. -Thank you. I would be
delighted to talk with you about the opportunities at Phision
Therapeutics. 10
Bridging Academia-Industry Barriers
Breandn N. Kennedy Ph.D. Senior Lecturer & Head of
PharmacologyUCD School of Biomolecular & Biomedical ScienceUCD
Conway [email protected]
Most Academic Research Groups Have The Ability To Commercialise
Research. Research Commercialisation Can Enhance Your Research
Infrastructure, Capacity And Outputs. Research Commercialisation
can Support Economic Development and New Employment. There Is A
Need For Academic Groups & Funding Charities To Enhance
Appreciation Of Research Commercialisation. Research
Commercialisation Is Challenging!
Executive Summary
Our Commercialisation Destinationso far..2009Research: Genetic
Regulators of Cone Photoreceptors. Research Funding: SFI, HRB,
MRCG/FB, AHAF. Industry Interaction: None.Innovation
/Commercialisation: Licence agreement w DanioLabs. 2015Research:
Discovery, Development & Delivery of Drugs for Blindness or
Cancer. Research Funding: EI, FP7 IAPP, ICS, IRC, WT-NIH, SFI, HRB,
MRCG/FB. Industry Interaction: GADEA (ES), KALVISTA (UK), RENASCI
(UK), EPA (US), FIRECREST/ICON (IE). Innovation /Commercialisation:
1 patent awarded, 3 PCT filings. Industry-Academia Staff
Exchanges.
Right Place, Right Time- Meeting with Dr. Ruth McMahon (EI).
Awareness of lack of commercialisation knowledge. Analysis of
Commercialisation Potential (EI & Nova UCD).IDF submitted to
UCD TTO.Awarded EI Proof-of-Concept award 2009-2010. Completed UCD
Innovation Workshop 2010.Completed UCD Campus Company Development
Programme 2011.Introduction to Consultant Medicinal Chemist.Awarded
EI Commercialisation Fund 2012 (3rd time lucky). Constructive
feedback enhanced research proposal.Priority/PCT patents filed and
awarded 2011-2015. Introduction to Industry Partners.Awarded FP7
Industry-Academia Partnership Programme Award.EI FP7 Co-ordinator
support. Our Commercialisation Journey
Significantly enhanced our research expertise.Expanded our
research team.Got us out of our comfort zoneLed to significant
follow-on funding.Generated patents and publications.Resulted in
research innovation awards.Enhanced career development of research
trainees.Greater Interaction with Pharma, Clinicians, VCs, TTO.
Enhanced likelihood that our technology can be developed to
clinic.Jobs, Spin-Outs
Benefits to Stakeholders
TerminologyMethod of Use, Composition of Matter, Prior Art,
NCE..Mind-sethow does it work Vs will someone buy/investpapers Vs
jobs. PatentingWork intensive.Non-disclosure.Costs.Market Research
and Engagement with Stakeholders.Commercial and Technical
Deliverables/Milestones. Gaining Trust, Building a
Network.Challenges/Opportunities in Commercialisation.
Dont assume your research has no commercial potential.Seek help
from commercialisation experts. Contact TTOs, submit IDFs. Review
EI, SFI & IRC innovation/commercialisation awards. Attend
innovation workshops/Venture Launch programmes.Build a network.
Advice
